Genprex boosts board with three biotechnology and healthcare industry leaders

Genprex Inc (NASDAQ:GNPX), the gene therapy group, has bolstered its board with three new directors as it executes on its key corporate initiatives. The trio are Brent Longnecker, CEO of Longnecker & Associates; Jose A. Moreno Toscano, CEO at LFB USA Inc; and William R. Wilson, Jr, chairman, president and CEO of Wilson Land & Cattle Co. READ: Genprex hires two accomplished life science executives as it advances strategic plan The appointments follows yesterday news that the firm has strengthened its management team with Catherine Vaczy, named executive vice president and chief strategy officer, and Michael Redman becoming executive vice president and chief operating officer. “We are honored to have Brent, Jose and Will join our Board in what we believe is a transformational time for our company,”  Rodney Varner, CEO of Genprex, said in a statement. "Their combined experience in regulatory compliance, business development, clinical trial management, and deal structuring will be invaluable as we continue to our develop gene therapy drug candidates and pursue partnerships for our drug candidates. The addition of these outstanding directors, together with our new senior executive hires and a significantly strengthened balance sheet, puts us in an excellent position to execute our plans." Longnecker has over three decades' experience in corporate governance, executive compensation, and risk management consulting for public, private, and non-profit organizations, while Moreno Toscano brings over 20 years' experience in the pharmaceutical and biotechnology industries. Wilson Jr has over 40 years of experience as an attorney, with legal experience spanning health care regulation, biotechnology, clinical trial management, nursing home licensing and regulation, physician accreditation, securities, corporate governance, and contractual matters. The company recently received Fast Track designation from the US Food and Drug Administration (FDA) for its lead drug candidate; raised more than US$26 million from institutional investors over the last few months; and also licensed a new gene therapy drug candidate for diabetes from the University of Pittsburgh. Contact the author at giles@proactiveinvestors.com